OTCMVPTDF
Market cap12mUSD
Jan 10, Last price
0.08USD
1D
-2.50%
1Q
-32.76%
Jan 2017
-1.76%
IPO
-98.11%
Name
VentriPoint Diagnostics Ltd
Chart & Performance
P/E
—
P/S
370.57
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.05%
Rev. gr., 5y
-3.95%
Revenues
49k
-27.85%
Net income
-5m
L-0.02%
CFO
-4m
L-8.05%
Earnings
Apr 28, 2025
Profile
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model of the heart chamber using echocardiograms and magnetic resonance imaging images; and obtain reproducible, accurate volumetric measurement, and ejection fraction. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and Covid-19 related heart issues. The company was incorporated in 2004 and is based in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 49 -27.85% | 68 | |||||||
Cost of revenue | 4,980 | 4,936 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,930) | (4,868) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 136 | ||||||||
Tax Rate | |||||||||
NOPAT | (4,930) | (5,004) | |||||||
Net income | (4,872) -0.02% | (4,873) 25.55% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 138 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 115 | 92 | |||||||
Long-term debt | 571 | 684 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (608) | (4,410) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (3,804) | (4,137) | |||||||
CAPEX | 4 | ||||||||
Cash from investing activities | |||||||||
Cash from financing activities | (102) | 88 | |||||||
FCF | (4,864) | (5,274) | |||||||
| Balance | |||||||||
Cash | 1,294 | 5,186 | |||||||
Long term investments | |||||||||
Excess cash | 1,292 | 5,182 | |||||||
Stockholders' equity | (10,725) | (5,868) | |||||||
Invested Capital | 11,058 | 10,880 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 156,824 | 155,994 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (4,864) | (4,817) | |||||||
EV/EBITDA | |||||||||
Interest | 67 | 28 | |||||||
Interest/NOPBT | |||||||||